58 recruiting, 56 unknown, 40 completed, 28 active not recruiting. 210 Phase 3, 24 Phase 2.
Follow Otorhinolaryngologic Neoplasms: new trials by email Literature Review of Otorhinolaryngologic Neoplasms trials Research Report on Otorhinolaryngologic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma Nanocrystalline Megestrol Acetate Oral Suspension, Placebo - Nasopharyngeal Cancinoma (NPC) | Phase 3 | Recruiting | Sun Yat-sen University | 204 | 2026-09-29 | 2026-10-15 |
| A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma CRB-701, capcitabine, Cetuximab (EGFR inhibitor) - Oropharyngeal Carcinoma (OPC) | Phase 3 | Recruiting | Corbus Pharmaceuticals Inc. | 260 | 2026-09-29 | 2026-10-08 |
| A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02) BL-B01D1, PD-1 monoclonal antibody, cisplatin - Nasopharyngeal Carcinoma (NPC) | Phase 3 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 404 | 2026-09-01 | 2026-09-15 |
| Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma Toripalimab combined with Nimotuzumab, Nimotuzumab - Nasopharyngeal Carcinoma (NPC) | Phase 3 | Recruiting | Sun Yat-sen University | 566 | 2026-07-20 | 2026-07-16 |
| GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC. Toripalimab, Anlotinib, Cisplatin - Nasopharyngeal Carcinoma | Phase 3 | Not yet recruiting | Sun Yat-sen University | 442 | 2026-05-08 | 2026-04-22 |
| RAIRI Model-Guided Adjuvant Therapy in Nasopharyngeal Carcinoma PD-1 inhibitor, Capecitabine - Nasopharyngeal Carcinoma (NPC) | Phase 3 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 651 | 2026-05-01 | 2026-06-04 |
| DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. Dabrafenib, Trametinib - Haematological Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2026-04-01 | 2026-08-17 |
| Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC Becotatug Vedotin, Sintilimab, Cisplatin - Nasopharyngeal Carcinoma (NPC) | Phase 3 | Recruiting | First Affiliated Hospital of Guangxi Medical University | 266 | 2026-03-05 | 2026-03-16 |
| Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma Anlotinib Hydrochloride Capsules, Gemcitabine (GEM), Cisplatin - Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer | Phase 3 | Not yet recruiting | Sun Yat-sen University | 412 | 2026-03-01 | 2026-02-03 |
| Surgery With or Without Neoadjuvant Treatment of SBRT Plus Chemoimmunotherapy in Resectable Locally Advanced Oral and HPV-unrelated Oropharyngeal Squamous Cell Carcinoma Neoadjuvant treatment of SBRT plus chemoimmunotherapy followed by surgery and postoperative radiotherapy or chemoradiotherapy, Surgery and postoperative radiotherapy or chemoradiotherapy - Oral Cancer, Oropharyngeal Cancer | Phase 3 | Not yet recruiting | Sun Yat-sen University | 184 | 2026-02-24 | 2026-02-11 |
| Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma tislelizumab, Gemcitabine + cisplatin (GP), Cisplatin (100mg/m2) - Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer | Phase 3 | Not yet recruiting | Sun Yat-sen University | 418 | 2026-01-15 | 2026-01-28 |
| Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial Intensity-Modulated Proton Therapy (IMPT), Intensity-Modulated Radiation Therapy (IMRT), Cisplatin - Nasopharyngeal Carcinoma (NPC) | Phase 3 | Recruiting | Man Hu | 300 | 2025-12-15 | 2026-01-14 |
| 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma Cisplatin-based induction chemotherapy, Full course of PD-1 monoclonal antibody, Reduced-dose radiotherapy to CTV2 - Nasopharyngeal Carcinoma | Phase 3 | Recruiting | Ming-Yuan Chen | 346 | 2025-11-20 | 2026-01-09 |
| Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy Full course of PD-1blockades, Cisplatin-based induction chemotherapy, Standard-dose radiotherapy - Nasopharyngeal Carcinoma (NPC) | Phase 3 | Recruiting | Ming-Yuan Chen | 456 | 2025-11-18 | 2026-01-09 |
| Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma. Radiation Therapy - Nasopharyngeal Cancinoma (NPC) | Phase 3 | Active not recruiting | Sun Yat-sen University | 700 | 2025-11-17 | 2026-08-27 |
| Steroids for Facial Nerve Function Protection in Post-surgical Vestibular Schwannoma Patients Steroids therapy, Placebo - Vestibular Schwannoma, Facial Nerve Paralysis | Phase 3 | Recruiting | Beijing Tiantan Hospital | 364 | 2025-10-09 | 2026-10-26 |
| Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC metronomic adjuvant chemotherapy with capecitabine - Nasopharyngeal Cancinoma (NPC) | Phase 3 | Active not recruiting | Chongqing University Cancer Hospital | 252 | 2025-10-04 | 2025-11-25 |
| Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC Individualized Neck Irradiation, Standard Neck Irradiation - Nasopharyngeal Carcinoma (NPC) | Phase 3 | Recruiting | Fudan University | 462 | 2025-09-01 | 2025-12-24 |
| Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer Reduced-Target Radiotherapy, Conventional Full-Target Radiotherapy - Nasopharyngeal Carcinoma (NPC) | Phase 3 | Recruiting | Ming-Yuan Chen | 166 | 2025-08-20 | 2025-12-09 |
| Shrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal Cavity standard CTV delineation, reduced CTV delineation - Nasopharyngeal Cancinoma (NPC) | Phase 3 | Not yet recruiting | Hai-Qiang Mai,MD,PhD | 550 | 2025-08-01 | 2025-07-18 |
Showing 20 of 210. Sign in to see all of them.
Nasopharyngeal Carcinoma (139) · Oropharyngeal Neoplasms (34) · Laryngeal Neoplasms (23) · Nasopharyngeal Neoplasms (23) · Head and Neck Neoplasms (21) · Hypopharyngeal Neoplasms (16) · Mouth Neoplasms (16) · Squamous Cell Carcinoma of Head and Neck (13) · Carcinoma (6) · Neoplasms (5) · Recurrence (5) · Neoplasm Metastasis (4) · Carcinoma, Squamous Cell (3) · Epstein-Barr Virus Infections (3) · Neuroma, Acoustic (3)
Otorhinolaryngologic Diseases (210) · Neoplasms by Site (206) · Neoplasms (205) · Stomatognathic Diseases (198) · Pharyngeal Diseases (195) · Pharyngeal Neoplasms (192) · Head and Neck Neoplasms (184) · Neoplasms by Histologic Type (159) · Nasopharyngeal Diseases (156) · Neoplasms, Glandular and Epithelial (156) · Carcinoma (150) · Nasopharyngeal Neoplasms (135) · Respiratory Tract Diseases (26) · Respiratory Tract Neoplasms (25)
Cisplatin (78) · Gemcitabine (41) · Radiotherapy, Intensity-Modulated (37) · Docetaxel (23) · Radiotherapy (21) · Capecitabine (20) · Fluorouracil (20) · toripalimab (12) · Drug Therapy (11) · camrelizumab (9) · Carboplatin (8) · Platinum (8) · 1,2-diaminocyclohexaneplatinum II citrate (7) · Magnetic Resonance Spectroscopy (7) · Cetuximab (6)
Sun Yat-sen University (71) · Fudan University (7) · National Cancer Institute (NCI) (7) · Groupe Oncologie Radiotherapie Tete et Cou (4) · Jiangxi Provincial Cancer Hospital (4) · Zhejiang Cancer Hospital (4) · Eye & ENT Hospital of Fudan University (3) · Fujian Cancer Hospital (3) · Gustave Roussy, Cancer Campus, Grand Paris (3) · Ming-Yuan Chen (3) · National Health Research Institutes, Taiwan (3) · XIANG YANQUN (3) · Cancer Research UK (2) · Centre Leon Berard (2) · First Affiliated Hospital of Guangxi Medical University (2)
China (137) · United States (29) · France (16) · Canada (11) · Taiwan (10) · United Kingdom (7) · Singapore (5) · Spain (4) · Australia (3) · Belgium (3) · Germany (3) · Hong Kong (3) · Puerto Rico (3) · Romania (3) · Switzerland (3)
Jun Ma, M.D. (7) · Ming-Yuan Chen, MD,PhD (6) · Ming-Yuan Chen, MD, PhD (4) · Fang-Yun Xie, M.D. (3) · Jun Ma, MD (3) · Chong Zhao, MD PhD (2) · Hai-Qiang Mai, MD,PhD (2) · Jean Bourhis, PhD (2) · Shaojun Lin, DR (2) · Xiaozhong Chen (2) · Xiaozhong Chen, MD (2) · Yanqun Xiang (2) · Yun-fei Xia, M.D (2) · Yun-fei Xia, MD (2)
PMID 31150573, PMID 27686945, PMID 28837405, PMID 29584545, PMID 35240053, PMID 38507662, PMID 39970442, PMID 27567280, PMID 30213452, PMID 33492986, PMID 34111416, PMID 34341578, PMID 35997729, PMID 36746459, PMID 37537541, PMID 39438442, PMID 40692081, PMID 40890288, PMID 41791006, PMID 10640954, PMID 11212235, PMID 15746043, PMID 15752890, PMID 15920746, PMID 16139912, PMID 16794899, PMID 17293228, PMID 19564532, PMID 21112774, PMID 21831465, PMID 22154591, PMID 22252927, PMID 22261362, PMID 23143190, PMID 24452791, PMID 25057165, PMID 25957714, PMID 26879049, PMID 27165613, PMID 27567279, PMID 27846913, PMID 27918720, PMID 28235726, PMID 28581397, PMID 28688693, PMID 28864073, PMID 29153464, PMID 29258695, PMID 29501366, PMID 30016391
U10CA180868 (5), U10CA180820 (3), 2014 (1), P30CA016042 (1), R01CA148707 (1), U10CA021661 (1), U10CA180821 (1)